EXHIBIT 99.1

FOR IMMEDIATE RELEASE

Investor Contact:
Neil Berkman Associates
(310) 277-5162
info@BerkmanAssociates.com Company Contact:
Chris Chavez, President & CEO
(972) 309-8000
www.ANS-medical.com

Advanced Neuromodulation Systems
Reports Third Quarter Results

     DALLAS, TEXAS, October 27, 2005 — Advanced Neuromodulation Systems, Inc. (ANS) (NASDAQ:ANSI) today announced operating results for the third quarter and first nine months of 2005.

Third Quarter Results

     For the three months ended September 30, 2005, revenue increased 25.6% to a record $39,337,000 from $31,330,000 for the third quarter of 2004. Sales of neuro products increased 28.3% to a record $36,199,000 for this year’s third quarter compared to $28,223,000 for last year’s third quarter, reflecting higher sales of ANS’ Eon^TM, Genesis^TM, and GenesisXP^TM implantable spinal cord stimulation (SCS) systems for the treatment of chronic pain. Gross margin for this year’s third quarter was 74.6% compared to 73.1% for the third quarter of 2004.

     Net income for the third quarter of 2005 increased 12.9% to $5,353,000, or $0.26 per diluted share, from $4,742,000, or $0.23 per diluted share, for the third quarter of 2004.

     At September 30, 2005, ANS had total cash and marketable securities of approximately $158.9 million. ANS has no debt.

Nine Month Results

     For the nine months ended September 30, 2005, revenue increased 24.8% to a record $110,366,000 from $88,451,000 for the first nine months of 2004. Neuro sales increased 24.6% to a record $99,771,000 compared to $80,084,000 for the same period last year. Net income for the first nine months of 2005 was a record $69,007,000, or $3.31 per diluted share. This compares to net income for the first nine months of 2004 of $13,034,000, or $0.62 per diluted share. Net income for this year’s first nine months included a pre-tax gain of $85,244,000 from the sale of Cyberonics, Inc. common stock acquired in August 2004.

St. Jude Medical Tender Offer

     On October 16, 2005, St. Jude Medical, Inc. and ANS announced that the Boards of Directors of both companies have unanimously approved a definitive agreement whereby St. Jude Medical will acquire ANS for $61.25 per ANS share in cash, for a total of approximately $1.3 billion. St. Jude Medical has commenced a tender offer for all of the outstanding shares of ANS common stock. The transaction is subject to customary closing conditions and regulatory approvals, as well as the valid tender of a majority of the outstanding shares of ANS common stock, on a fully-diluted basis. The transaction is expected to close by the end of the year.

Advanced Neuromodulation Systems Reports Third Quarter Results
October 27, 2005
Page Two

About Advanced Neuromodulation Systems

     ANS (www.ANS-medical.com) designs, develops, manufactures and markets implantable systems used to manage chronic intractable pain and other disorders of the central nervous system.

Forward-Looking Statements

     Any statements made regarding the proposed transaction between St. Jude Medical, Inc. and Advanced Neuromodulation Systems, Inc. are forward-looking statements, which are subject to risks and uncertainties, such as those described under or incorporated by reference in Item 8.01 of St. Jude Medical’s Current Report on Form 8-K filed on October 17, 2005, and in Item 8.01 of ANS’ Current Report on Form 8-K filed on October 17, 2005, and in the Outlook and Uncertainties section in ANS’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 (see page 25) and ANS’ Annual Report on Form 10-K for the year ended December 31, 2004 (see page 26). Actual results may differ materially from anticipated results.

Additional Information

     This press release constitutes neither an offer to purchase nor a solicitation of an offer to sell shares of ANS. St. Jude Medical has filed a tender offer statement with the Securities and Exchange Commission (SEC) and ANS has filed a solicitation/recommendation statement with respect to the offer. ANS shareholders are advised to read the tender offer statement regarding the acquisition of ANS referenced in this news release, and the related solicitation/recommendation statement. The tender offer statement and the solicitation/recommendation statement contain important information that should be read carefully before any decision is made with respect to the offer. These documents are available to all shareholders of ANS at no expense to them. These documents are also available at no charge on the SEC’s web site at www.sec.gov. Shareholders may also obtain copies of these documents without charge by requesting them from ANS in writing at 6901 Preston Road, Plano, Texas 75024, or by phone at 972-309-8000.

(tables attached)

#3982

ADVANCED NEUROMODULATION SYSTEMS, INC. and SUBSIDIARIES
Condensed Consolidated Statements of Income (Unaudited)

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2005			2004		2005			2004
Net revenue	$	39,337,376		$	31,330,408	$	110,366,066		$	88,451,122
Cost of revenue		10,003,026			8,414,174		28,925,278			23,751,017
Gross profit		29,334,350			22,916,234		81,440,788			64,700,105
Operating expenses:
Sales and marketing		12,411,385			9,791,838		34,553,480			27,810,611
Research and development		4,524,520			2,911,698		12,314,218			8,096,308
General and administrative		4,258,188			2,974,620		11,609,568			7,998,316
Amortization of other intangibles		662,773			626,191		1,960,300			1,824,838
		21,856,866			16,304,347		60,437,566			45,730,073
Income from operations		7,477,484			6,611,887		21,003,222			18,970,032
Other income (expense):
Gain on sale of investment in common stock of Cyberonics, Inc.		—			—		85,244,301			—
Foreign currency transaction gain (loss)		(5,793	)		81,009		(170,608	)		26,156
Investment income		957,473			482,850		2,595,591			964,021
		951,680			563,859		87,669,284			990,177
Income before income taxes		8,429,164			7,175,746		108,672,506			19,960,209
Income taxes		3,076,645			2,433,791		39,665,465			6,926,251
Net income	$	5,352,519		$	4,741,955	$	69,007,041		$	13,033,958
Basic income per share:
Net income	$	0.27		$	0.23	$	3.46		$	0.65
Number of basic shares		19,800,456			20,189,242		19,948,489			20,075,233
Diluted income per share:
Net income	$	0.26		$	0.23	$	3.31		$	0.62
Number of diluted shares		20,938,453			21,032,695		20,857,866			21,116,735

ADVANCED NEUROMODULATION SYSTEMS, INC. and SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)

	September 30,		December 31,
	2005		2004
Assets
Current assets:
Cash and marketable securities	$	158,882,578	$	124,016,064
Receivable, trade net		29,791,124		25,322,813
Receivable, investment income and other		1,722,025		638,987
Inventories		25,362,383		23,923,851
Deferred income taxes		2,072,228		2,029,091
Prepaid expenses and other current assets		1,967,525		1,888,957
Total current assets		219,797,863		177,819,763
Net property, equipment and fixtures		35,149,222		33,175,329
Minority equity investments in preferred stock		1,104,000		1,104,000
Goodwill, patents, tradenames, purchased technology & other assets, net		34,709,388		35,388,049
Total assets	$	290,760,473	$	247,487,141
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	3,237,598	$	3,206,516
Accrued salary and employee benefit costs		3,732,694		2,390,721
Accrued commissions		3,060,412		2,656,112
Income taxes payable		8,299,711		708,412
Deferred revenue		107,028		165,861
Other accrued expenses		1,043,682		342,075
Total current liabilities		19,481,125		9,469,697
Deferred income taxes		6,055,263		14,734,487
Non-current deferred revenue		616,849		718,820
Total stockholders’ equity		264,607,236		222,564,137
Total liabilities and stockholders’ equity	$	290,760,473	$	247,487,141